Assenagon Asset Management S.A. Has $7.09 Million Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Assenagon Asset Management S.A. raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 93.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 89,777 shares of the specialty pharmaceutical company’s stock after acquiring an additional 43,449 shares during the period. Assenagon Asset Management S.A. owned approximately 0.40% of ANI Pharmaceuticals worth $7,087,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Divisadero Street Capital Management LP acquired a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $21,454,000. Campbell & CO Investment Adviser LLC bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $1,597,000. Decker Retirement Planning Inc. raised its holdings in shares of ANI Pharmaceuticals by 76,862.5% in the third quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock valued at $3,384,000 after purchasing an additional 36,894 shares during the last quarter. Apis Capital Advisors LLC lifted its position in ANI Pharmaceuticals by 28.1% during the 3rd quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after buying an additional 36,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $2,137,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $72.82 on Friday. The firm’s fifty day moving average price is $77.59 and its two-hundred day moving average price is $83.86. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The company has a market cap of $1.63 billion, a P/E ratio of 21.67 and a beta of 0.52. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 2,084 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total transaction of $161,572.52. Following the transaction, the senior vice president owned 50,993 shares in the company, valued at $3,953,487.29. This represents a 3.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Christopher Mutz sold 5,323 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $78.02, for a total transaction of $415,300.46. Following the transaction, the insider directly owned 84,840 shares in the company, valued at $6,619,216.80. This represents a 5.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 27,860 shares of company stock valued at $2,114,771 in the last three months. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target for the company. Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $107.33.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.